A. S. Musiienko

A. S. Musiienko

Auto-generated profile, based on publicly available information

A. S. Musiienko

State Institution “D.F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
NGNataliia Grygorieva
Nataliia Grygorieva
VKV.M. Kovalenko
V.M. Kovalenko
МКМ.о. Коrzh
М.о. Коrzh
TTT.F. Tatarchuk
T.F. Tatarchuk
NDN.V. Dedukh
N.V. Dedukh
ECE.F. Chaykivska
E.F. Chaykivska
Background. Postmenopausal osteoporosis (PMO), which is developed due the estrogen defi ciency in women after menopause, is the most common type of systemic osteoporosis. The latest Ukrainian recommendation for its management requires revision due to new data from high-quality research performed in recent years. The purpose was to develop a guideline on the diagnosis, prevention, and treatment of PMO based on an analytical analysis of modern literary sources in order to improve the awareness of the medical community of Ukraine. Methodology. To develop the guideline, an expert group of 13 leading Ukrainian scientists of various specialties was created who conducted a tho rough review of modern literature on this topic, assessed the level of existing evidence using the GRADE system, proposed and voted on 15 recommendations of the guideline. Results. The guideline contains chapters on diagnosis and diff erential diagnosis of PMO, assessment of the osteoporotic fracture risk, the role of bone turnover markers in the management of PMO, and modern strategies of antiosteoporotic treatment. Conclusions. The Ukrainian guideline on the diagnosis, prevention, and treatment of PMO, which contains 15 main recommendations, created on the basis of a tho rough analysis and synthesis of modern literature data, is an important tool for the management of PMO and is recommended by Ukrainian Association of Osteoporosis for use in Ukrainian me dical community.

27 March 2023 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
NGNataliia Grygorieva
Nataliia Grygorieva
TST.YU. Solonenko
T.YU. Solonenko
AMA.S. Musiienko
A.S. Musiienko
Background. Data from numerous studies indicate a significant prevalence of vitamin D deficiency in Ukraine and the world. In recent years, the Ukrainian medical community has faced two important challenges — the COVID-19 pandemic and the russian aggression, which significantly affected the organization and availability of medical care. Despite the previous epidemiological studies in Ukraine devoted to the vitamin D status, there are no data during the past 5 years that became the background for this research. The purpose was to analyze the vitamin D status in the adult population of Ukraine during the COVID-19 pandemic and russian aggression. Materials and methods. Data of the serum level of 25-hydroxyvitamin D (25(OH)D) in 5029 adults aged 20–99 years, who for various reasons applied for its measurement, were retrospectively analyzed. The analysis was performed depending on the year and month of observation, the age and gender of the subjects, and the 25(OH)D level. Results. The mean serum level of 25(OH)D in the total group was 33.2 [24.1–43.8] ng/ml. The assessment of the number of 25(OH)D tests for 2018–2022 did not reveal any significant differences in 2018 and 2019 but established a significant decrease during the russian aggression in Ukraine in 2022 (by 55.7%) compared to 2018, as well as indices during the COVID-19 pandemic (by 21.6 % compared to 2020, by 23.5 % in 2021). During the observation period, it was established a decrease in the vitamin D deficiency proportion from 20.6 % in 2018 to 9.3 % in 2022, and an increase in the proportion of subjects with suboptimal (from 6.6 to 11.4 %, respectively) and high serum concentrations of 25(OH)D (from 2.2 to 12.7 %). Conclusions. Our results indicate a grown serum 25(OH)D level during 2020–2022 in the adult population of Ukraine compared to the indices of previous years and a decreased share of vitamin D deficiency in the Ukrainian population. In addition, a decrease in the number of 25(OH)D level tests was established, especially during the period of the russian aggression, which should be taken into account during the planning measures to optimize the vitamin D status in the adult population of Ukraine.

14 March 2023 in BMC Nutrition
Verified
Journal Article
Open access
PDF file
NGNataliia Grygorieva
Nataliia Grygorieva
TST. Yu. Solonenko
T. Yu. Solonenko
AMA. S. Musiienko
A. S. Musiienko
MBM. A. Bystrytska
M. A. Bystrytska
Background: Data from numerous studies demonstrate the high frequency of vitamin D deficiency (VDD) and insufficiency (VDI) in many countries worldwide that depend on age and sex, seasons, country, and concomitant pathology. This research aimed to study vitamin D status in the Ukrainian population during 2016–2022 years depending on age, sex, month, and year of the observation, and compare the results with the data of previous Ukrainian epidemiologic studies. Methods: In a single-center cohort study, we analyzed the serum total 25-hydroxyvitamin D (25(OH)D) level in 7,418 subjects aged 20–99 years. The analysis was performed depending on age, sex, month, season, and year of the observation. Also, we compared the results with the data of previous Ukrainian studies. 25(OH)D level was measured using the electrochemiluminescence method. Results: The mean serum 25(OH)D level in the total group was 31.0 [22.3–41.1] ng/mL, the lowest level was in the age group 90–99 years old. No gender differences were found in 25(OH)D levels, except the one for the women aged 60–69 years old who had higher vitamin D levels compared to male parameters. 41.6% of the subjects had an optimal (> 30–50 ng/mL) 25(OH)D level, 27.3% had VDI, and 19.5% had a VDD. The suboptimal and high serum concentration of 25(OH)D (> 50–100 ng/mL) was found in 11.4% of the subjects. Also, we established the increase of serum 25(OH)D level from 2016 to 2022 with the highest values in 2020–2022. Seasonal variations of 25(OH)D concentration confirmed the highest index in autumn (33.0 [24.0–42.4] ng/mL) and the lowest one in the spring (28.5 [19.7–38.7] ng/mL) with the highest 25(OH)D level in September and the lowest one in March. Conclusion: Our results confirmed a decrease in VDD and VDI in 2020–2022 in the Ukrainian population compared to the previous years (2016–2019) and previous Ukrainian studies with similar age and seasonal particularities. It may be the consequence of an improvement in public awareness of global vitamin D deficiency, its positive skeletal and extra-skeletal effects, as well as more intensive vitamin D supplementation due to the COVID-19 pandemic in the recent years.

30 June 2021 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
VPV.V. Povoroznyuk
V.V. Povoroznyuk
HJH. Johansson
H. Johansson
NGNataliia Grygorieva
Nataliia Grygorieva
JKJ.A. Kanis
J.A. Kanis
АMА.S. Musiіenko
А.S. Musiіenko
Enwu LiuEnwu Liu
Enwu Liu
Background. At present, FRAX is a well-known and widely-used risk assessment tool for major osteoporotic fractures. The Ukrainian version of the FRAX algorithm was presented in 2016; with the “intervention threshold” for additional DXA exa­mination and antiosteoporotic treatment of the Ukrainian women published in 2019. However, the data on its possible uses in men are limited. The purpose of the study was to evaluate the possibilities of using the previously developed criteria of the Ukrainian FRAX algorithm in Ukrainian men. Materials and me­thods. We exa­mined 653 outpatients aged 40–88 years (mean age (M ± SD) — 60.5 ± 11.8 years). We analyzed the results both in the general group and in the age subgroups; in particular, with an account of low-trauma fractures, included in the FRAX calculation, and compared them with the corresponding indices of the Ukrainian wo­men. Results. The most frequent (26.6 %) risk factor for osteoporo­tic fractures in the group of Ukrainian men was a history of low-trauma fracture (the corresponding index in women was 51.3 %), its presence being the reason for antiosteoporotic treatment initia­ting. Following upon the risk of major osteoporotic fractures calculated by FRAX, only 6.7 % of men without previous fractures were found to require additional DXA examination in order to re-evaluate the osteoporotic fracture risk, and none had a high fracture risk. 73 % of men without fractures did not have any risk factor inclu­ded in the FRAX algorithm. Conclusions. This study showed a grea­ter need for both antiosteoporotic treatment without DXA assessment and additional densitometric examination for the osteoporotic fracture risk assessment for the Ukrainian women rather than men, along with a special attention to the presence of previous fractures in men, and consideration of other risk factors for osteoporosis, even those not included in this FRAX algorithm.

8 September 2024 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
NGNataliia Grygorieva
Nataliia Grygorieva
VKV.M. Kovalenko
V.M. Kovalenko
МКМ.о. Коrzh
М.о. Коrzh
TRTronko
Tronko
IGI.YU. Golovach
I.YU. Golovach
TKT.A. Karasevska
T.A. Karasevska
Introduction. Glucocorticoid-induced osteoporosis (GIOP) is a bone metabolic disease that develops as a result of glucocorticoid (GC) use, is one of the most frequent causes of secondary osteoporosis, leads to an increase in the risk of low-energy fractures, disability and mortality of GC users. Despite the few stu­dies conducted in Ukraine on the epidemiology and treatment of GIOP, there have been no national recommendations for its ma­nagement until now, which has become the background for their creation. The purpose was to develop national guidelines for the diagnosis, prevention, and treatment of GIOP based on the analytical analysis of modern literary sources to improve the awareness of the medical community of Ukraine, improve management, and reduce the socio-economic burden of the disease. Materials and ­methods. A group of 18 experts, leading Ukrainian scientists in various fields, was created to develop the guideline. An analysis of current literary sources on epidemiology, risk factors, diagnosis, prevention and treatment of GIOP, and monitoring of the effectiveness and safety of its treatment was carried out. Evidence was synthesized ­using the GRADE system, and a critical assessment of the quality of the recommendations was carried out using the AGREE II tool. ­Results. The guideline consists of 12 provisions on screening, diagnosis, prevention, and treatment of GIOP. The authors emphasized the need to increase the awareness of the medical community of Ukraine regarding the problem, as well as patients regarding the possible side effects of GC. They presented the features of the clinical assessment of the osteoporotic fracture risk in GC users, as well as modern and available in Ukraine methods of diagnosis and treatment of GIOP. Conclusion. The first Ukrainian guideline for screening, diagnosis, prevention, and treatment of GIOP is an important national tool for its management, which is recommended by the Board of the Ukrainian Association of Osteoporosis for use in practical health care by doctors of various specialties.

26 March 2021 in PAIN, JOINTS, SPINE
Verified
Journal Article
Open access
PDF file
VPV.V. Povoroznyuk
V.V. Povoroznyuk
AMA.S. Musiienko
A.S. Musiienko
NZN.V. Zaverukha
N.V. Zaverukha
ATA.A. Tkachuk
A.A. Tkachuk
Целью исследования было изучение эффективности и безопасности терапии препаратом Фастум® гель у лиц с болью в нижней части спины (БНЧС) на фоне дегенеративно-дистрофических изменений позвоночника. Материалы и методы. Обследованы 24 человека мужского и женского пола в возрасте 50–69 лет с БНЧС продолжительностью более 14 дней с последующим делением на две группы. Группа I — 12 пациентов, получавших кетопрофен в виде аппликаций тонким слоем на поясничную область 2 раза в сутки в течение 10 дней. Группа II — 12 пациентов, которым проводили аппликации вазелина тонким слоем на тот же участок 2 раза в сутки в течение 10 дней. Пациенты применяли исследуемые препараты в качестве монотерапии. Обследование проводили перед началом терапии и на 10-й и 20-й день лечения. Результаты. У пациентов, получавших аппликации кетопрофеном, достоверно снижалась интенсивность боли по четырем составляющим визуально-аналоговой шкалы и опроснику Роланда — Морриса. Вместе с этим достоверно улучшались функциональные возможности согласно результатам теста Шобера (t = 3,54, р = 0,005) и Томайера (t = 3,08, р = 0,01). По результатам шкалы EuroQul-5D показатели качества жизни у пациентов, применявших локальную форму кетопрофена, достоверно улучшились на 45 % (t = 4,19, р = 0,002), на 39,3 % согласно анкете Освестри через 10 суток лечения (t = 3,9, р = 0,002). 75 % пациентов основной группы и 33,3 % группы сравнения оценили эффективность лечения как высокую согласно индексу Ликерта. В обеих группах не было зарегистрировано ни одного локального и системного побочного эффекта. Выводы. Кетопрофен гель в виде монотерапии достоверно снижал интенсивность болевого синдрома и улучшал функциональные возможности больных с БНЧС. Отсутствие побочных эффектов при лечении препаратом свидетельствует о его высоком профиле безопасности для пациентов.